Robert Tansley MBBS MBA

Morphogen-IX The Board

After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche, where he led the clinical team for the regulatory approval of Valcyte®.

Robert then joined the Cambridge-based company Arakis and worked as Medical Director until its £106 million sale to Sosei Inc.  Since that acquisition, he has been involved in a number of start-up companies, including founding and being CEO of the malaria-focused company Treague and being founding CEO of the University of Copenhagen spin-out Avilex Pharma.  In addition he was part of the founding management team of the now NASDAQ-listed KalVista Pharmaceuticals Limited, which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Robert qualified in medicine from University College London.  He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.

Robert manages CIC's investments in Abcodia, CMR Surgical, Carrick Therapeutics, Inivata, Microbiotica and Morphogen-IX .

Developing BMPs as novel treatments for pulmonary arterial hypertension